SinoMab Signs 3-Year Biomedicine R&D Deal with Hong Kong Institute

MT Newswires Live

Aug 13

SinoMab BioScience (HKG:3681) has signed a three-year agreement with Sun Yat-sen University Institute of Advanced Studies, Hong Kong, to jointly conduct research and development in biomedicine, according to a Tuesday bourse filing.

Shares of the biopharmaceutical firm fell over 2% in Wednesday's midday trade.

The partnership covers joint research, shared use of Shenzhen-based laboratory facilities, technical support for regulatory engagement, and training programs, with links to the University of Oxford.

SinoMab will provide at least one drug candidate for clinical development in the US and China and fund SYSU-IAS HK$1 million per quarter to support the projects.

The deal aims to accelerate innovative drug development and promote the translation of scientific research into clinical applications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2559679771"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559679771\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559679771?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 13:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559679771","market":"sh","top_or_hot":-1,"title":"SinoMab Signs 3-Year Biomedicine R&D Deal with Hong Kong Institute","media":"MT Newswires Live","content":"<html><body><p> SinoMab BioScience (HKG:3681) has signed a three-year agreement with Sun Yat-sen University Institute of Advanced Studies, Hong Kong, to jointly conduct research and development in biomedicine, according to a Tuesday bourse filing.</p><p>Shares of the biopharmaceutical firm fell over 2% in Wednesday's midday trade.</p><p>The partnership covers joint research, shared use of Shenzhen-based laboratory facilities, technical support for regulatory engagement, and training programs, with links to the University of Oxford.</p><p>SinoMab will provide at least one drug candidate for clinical development in the US and China and fund SYSU-IAS HK$1 million per quarter to support the projects.</p><p>The deal aims to accelerate innovative drug development and promote the translation of scientific research into clinical applications.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SinoMab Signs 3-Year Biomedicine R&D Deal with Hong Kong Institute</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinoMab Signs 3-Year Biomedicine R&D Deal with Hong Kong Institute\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-13 13:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> SinoMab BioScience (HKG:3681) has signed a three-year agreement with Sun Yat-sen University Institute of Advanced Studies, Hong Kong, to jointly conduct research and development in biomedicine, according to a Tuesday bourse filing.</p><p>Shares of the biopharmaceutical firm fell over 2% in Wednesday's midday trade.</p><p>The partnership covers joint research, shared use of Shenzhen-based laboratory facilities, technical support for regulatory engagement, and training programs, with links to the University of Oxford.</p><p>SinoMab will provide at least one drug candidate for clinical development in the US and China and fund SYSU-IAS HK$1 million per quarter to support the projects.</p><p>The deal aims to accelerate innovative drug development and promote the translation of scientific research into clinical applications.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03681","symbol_name":"中国抗体-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2559679771","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559679771","pubTimestamp":1755061672,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"SinoMab BioScience  has signed a three-year agreement with Sun Yat-sen University Institute of Advanced Studies, Hong Kong, to jointly conduct research and development in biomedicine, according to a Tuesday bourse filing.Shares of the biopharmaceutical firm fell over 2% in Wednesday's midday trade.The partnership covers joint research, shared use of Shenzhen-based laboratory facilities, technical support for regulatory engagement, and training programs, with links to the University of Oxford.SinoMab will provide at least one drug candidate for clinical development in the US and China and fund SYSU-IAS HK$1 million per quarter to support the projects.The deal aims to accelerate innovative drug development and promote the translation of scientific research into clinical applications.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03681":"中国抗体-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"SinoMab与香港研究所签署为期3年的生物医药研发协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03681":0.9},"content_text":"SinoMab BioScience (HKG:3681) has signed a three-year agreement with Sun Yat-sen University Institute of Advanced Studies, Hong Kong, to jointly conduct research and development in biomedicine, according to a Tuesday bourse filing.Shares of the biopharmaceutical firm fell over 2% in Wednesday's midday trade.The partnership covers joint research, shared use of Shenzhen-based laboratory facilities, technical support for regulatory engagement, and training programs, with links to the University of Oxford.SinoMab will provide at least one drug candidate for clinical development in the US and China and fund SYSU-IAS HK$1 million per quarter to support the projects.The deal aims to accelerate innovative drug development and promote the translation of scientific research into clinical applications.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}